Details

Autor(en) / Beteiligte

• Dressler, Dirk
• Bhidayasiri, Roongroj
• Bohlega, Saeed
• Chahidi, Abderrahmane
• Chung, Tae Mo
• Ebke, Markus
• Jacinto, L. Jorge
• Kaji, Ryuji
• Koçer, Serdar
• Kanovsky, Petr
• Micheli, Federico
• Orlova, Olga
• Paus, Sebastian
• Pirtosek, Zvezdan
• Relja, Maja
• Rosales, Raymond L.
• Sagástegui-Rodríguez, José Alberto
• Schoenle, Paul W.
• Shahidi, Gholam Ali
• Timerbaeva, Sofia
• Walter, Uwe
• Saberi, Fereshte Adib

Titel

Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force

Ist Teil von

• Journal of neurology, 2017, Vol.264 (1), p.112-120

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.